share_log

Mesoblast to Submit FDA Application for Ryoncil in Treating Pediatric GVHD

Benzinga ·  Jul 1 02:57

Mesoblast Limited (NASDAQ:MESO, ASX:MSB))))), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD) with the U.S. Food and Drug Administration (FDA) next week.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment